Immunomedics, Inc.

Overview

Immunomedics, Inc. is a biopharmaceutical company known for developing antibody-drug conjugates for the treatment of cancer. It is a subsidiary of Gilead Sciences, Inc., which acquired the company to strengthen its oncology portfolio.

Therapeutic areas

API / Drug Master Files

Immunomedics, Inc. holds 2 active (5 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• IMC1074 AS A LINKER-PAYLOAD INTERMEDIATE FOR ANTIBODY DRUG CONJUGATEActive2026-03-23
• IMC1014 AS A LINKER-PAYLOAD INTERMEDIATE FOR ANTIBODY DRUG CONJUGATEActive2026-01-23
• MURINE MONOCLONAL ANTIBODY AND F(AB)2 FRAGMENT (IMMU-14) TO CARCINOEMBRYONIC ANTIGEN (CEA)Inactive1990-09-14
• MURINE MONOCLONAL ANTIBODY (IMM-LL-2) TO B-CELL LYMPHOMA AND LEUKEMIA CELLSInactive1989-11-02
• MURINE MONOCLONAL ANTIBODY (IMMU-31) TO ALPHA-FETOPROTEINInactive1989-04-28

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Immunomedics, Inc. in our records. PharmaTek screens the full directory against live FDA enforcement data.